Evaluation of the Cost of Treatment on Endometriosis in the Hungarian Public-Funded Healthcare System
Author(s)
Dalma Pónusz-Kovács, MSc1, Luca F. Kajos, MSc1, Tímea Csákvári, MSc, PhD2, Róbert Pónusz, MSc, PhD1, Bettina Kovács, MSc1, Kálmán Kovács, MD, Ph.D., Habil3, József Bódis, MD, Ph.D., Habil3, Imre Boncz, MSc, PhD, MD1;
1University of Pécs, Faculty of Health Sciences, Institute for Health Insurance, Pécs, Hungary, 2University of Pécs, Faculty of Health Sciences, Institute for Health Insurance, Zalaegerszeg, Hungary, 3University of Pécs, National Laboratory on Human Reproduction, Pécs, Hungary
1University of Pécs, Faculty of Health Sciences, Institute for Health Insurance, Pécs, Hungary, 2University of Pécs, Faculty of Health Sciences, Institute for Health Insurance, Zalaegerszeg, Hungary, 3University of Pécs, National Laboratory on Human Reproduction, Pécs, Hungary
Presentation Documents
OBJECTIVES: Endometriosis is one of the most common gynecological diseases that could lead to infertility. The aim of quantitative, descriptive, and cross-sectional study is to analyze the annual nationwide health insurance treatment direct costs of endometriosis in Hungary in the year 2010 and in 2019.
METHODS: The data used in the research was from publicly funded national real-world datasets administered by the National Health Insurance Administration (NHIFA). The total number of cases of endometriosis in the Hungarian population was determined by WHO ICD codes and by types of the delivered treatment. The annual health insurance expenditure in total and per capita, by age groups and by the type of treatment was evaluated in the year of 2010 and 2019.
RESULTS: In 2010, NHIFA funded the treatment of patients diagnosed with endometriosis with a total of 1,639,613 EUR (1,15 million USD). In 2019, the amount of funding was 16.2% higher, reaching almost 2 million EUR [(1,905,476 EUR) (3,13 million USD)]. The average annual health insurance expenditure per capita was 574 EUR (401 USD) in 2010 and 426 EUR (476 USD) in 2019. The cost of subsidized medications comprised the largest share of expenditure (2010. 48,8%; 2019. 48,2%). By age group, the highest per capita expenditure in 2010 was in the 20-29-year age group (697 EUR, 487 USD), followed by patients aged 30-39 (689 EUR, 484 USD). In 2019, expenditure represented a slightly lower cost compared to 2010 (−25.8%). The highest costs were among the 20-29-year age group, followed by 30-39- and 40-49-year-old patients.
CONCLUSIONS: The number of endometriosis cases is increasing. Early diagnosis and targeted treatment, while reducing endometriosis symptoms, would improve patients' quality of life and reduce health insurance costs. The establishment of endometriosis centers would have a significant impact on effective patient outcomes.
METHODS: The data used in the research was from publicly funded national real-world datasets administered by the National Health Insurance Administration (NHIFA). The total number of cases of endometriosis in the Hungarian population was determined by WHO ICD codes and by types of the delivered treatment. The annual health insurance expenditure in total and per capita, by age groups and by the type of treatment was evaluated in the year of 2010 and 2019.
RESULTS: In 2010, NHIFA funded the treatment of patients diagnosed with endometriosis with a total of 1,639,613 EUR (1,15 million USD). In 2019, the amount of funding was 16.2% higher, reaching almost 2 million EUR [(1,905,476 EUR) (3,13 million USD)]. The average annual health insurance expenditure per capita was 574 EUR (401 USD) in 2010 and 426 EUR (476 USD) in 2019. The cost of subsidized medications comprised the largest share of expenditure (2010. 48,8%; 2019. 48,2%). By age group, the highest per capita expenditure in 2010 was in the 20-29-year age group (697 EUR, 487 USD), followed by patients aged 30-39 (689 EUR, 484 USD). In 2019, expenditure represented a slightly lower cost compared to 2010 (−25.8%). The highest costs were among the 20-29-year age group, followed by 30-39- and 40-49-year-old patients.
CONCLUSIONS: The number of endometriosis cases is increasing. Early diagnosis and targeted treatment, while reducing endometriosis symptoms, would improve patients' quality of life and reduce health insurance costs. The establishment of endometriosis centers would have a significant impact on effective patient outcomes.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
HPR105
Topic
Health Policy & Regulatory
Topic Subcategory
Insurance Systems & National Health Care, Public Spending & National Health Expenditures
Disease
SDC: Reproductive & Sexual Health